We plan to issue several type 2 diabetes blog postings in the coming weeks to highlight findings from a recently published report entitled TreatmentTrends: Type 2 Diabetes. This report provides insights into physician perceptions of type 2 diabetes, based on primary market research of 102 U.S. Endocrinologists (ENDOs) and 55 U.S. PCPs. For this week, here is a key question and summary findings from the report:
- What is the preference for certain type 2 diabetes drug classes or brands?
- TreatmentTrends Type 2 Diabetes (US) covers many of the major classes of type 2 diabetes treatment, including biguanides (metformin), long-acting insulin analogues, DDP-IV inhibitors, short-acting insulin analogues, PPAR-gamma agonists, GLP-1 receptor agonists, and SGLT-2 inhibitors, among many others. Currently, a majority of type 2 diabetes patients are using metformin (excluding fixed-dose combinations) and one-third of patients are treated with long-acting insulins such as Sanofi's Lantus or Novo Nordisk's Levemir.
Please see additional information in the report regarding what is the physician perception of the drug treatment rate for prediabetics and type 2 diabetics. Also, the report contains information on the average length of time on diabetes treatments, as the following diagram depicts: